Loading...
Intensifying Competition And Regulatory Burdens Will Hurt Synthetic Biology Revenue
AnalystLowTarget's Fair Value
US$9.00
64.7% overvalued intrinsic discount04 Sep
US$14.82
1Y
77.7%7D
1.6%1Y
77.7%7D
1.6%You can edit this narrative until Aug 9 10:11 PM. Then, changes will post as Updates.